Regeneus in commercialisation discussions reduces costs in review

(MENAFN - ProactiveInvestors)

Regenerative medicine company Regeneus Ltd () will increase its focus on partnering to commercialise its products as well as streamline operations and reduce costs.

The company is in discussions with potential partners about the licensing development and distribution of its allogeneic stem cell products.

In a wide reaching strategic review of operations outlined at the recent AGM the successful measures and cost reductions will see Regeneus on track to meet its reduced quarterly cash burn target of 1.7 million.

Significantly this will provide an expected two year cash runway.

Completion of the early stage research and development phases for a number of products now allows a greater focus on partnering and commercialisation.

New CEO John Martin said: our review identified a number of opportunities for streamlining our management structure and operations without having any significant impact on meeting our business and product development milestones for the next 18 months.

"We have increased our focus on licensing commercialisation partners for the co-development and distribution of products. HiQCell Kvax and our stem cell secretions cream are all at the stage where they can be commercialised and we are currently engaged with a number of parties about the distribution of these products.

"We are also in discussions with potential partners about the licensing development and distribution of our allogeneic stem cell products CryoShot and Progenza (PRG).

Martin said further: We have successfully completed an expensive phase in the development of our products. The Kvax vaccine manufacturing process is complete and has been transferred to Hennessey our manufacturing partner in the US.

The rest is here:
Regeneus in commercialisation discussions reduces costs in review